FSD Pharma Inc. (HUGE) Acquires Lucid Psycheceuticals for $9M
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
FSD Pharma Announces Definitive Agreement to Acquire Lucid Psycheceuticals
August 25, 2021 9:00 AM EDTAcquisition Advances Companys Strategic Plan Toward a Diversified Novel Drug Development Pipeline in Psychedelics and Medical Cannabis
TORONTO, Aug. 25, 2021 (GLOBE NEWSWIRE) -- FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) (FSD Pharma or the Company), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions in legal psychedelics and medical cannabis, announces today it has entered a definitive agreement to acquire 100% of the issued and outstanding shares Lucid Psycheceuticals Inc. (Lucid), a Canadian-based specialty psychedelic... More
